Clinical Trial Update: Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical study investigating apatinib as second-line therapy for malignant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Malignant Melanoma | Phase 2 | Status: UNKNOWN